 Expects to enroll first patient in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty in Japan in 1Q23 Extended cash runway into 2H24 MIAMI, Jan. 06, 2023 GLOBE NEWSWIRE Longeveron Inc. NASDAQ: LGVN Longeveron or Company, a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided ... The post UPDATE Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones appeare... 